We launched www.dtxpolicylandscape.org as a resource for ecosystem stakeholders, policymakers, and payors to engage, identify harmonizable standards, and scale best practices to enable the development of sound and enabling policies. Join our effort to deliver scalable, equitable digital healthcare to patients globally!
This DTx Policy Report is the result of semi-structured interviews with multistakeholder experts, and in-depth knowledge and expertise from DTA and EVERSANA (formerly Healthware).
The DMD/DTx Policy scenario is currently evolving. We analyzed existing frameworks and integrated insights on emerging trends and will regularly update the Report, to monitor and contribute to the evolving scenario.
We mapped fit-for-purpose requirements and categorized appraisal criteria, applying the common “lens” of the HTA Core Model® to identify areas of converging standards.
In June 2022, the Digital Therapeutics Alliance (DTA) and EVERSANA (formerly Healthware Group) announced a partnership to form a coalition convening thought leaders, policymakers, and professional and trade associations from across the European region to discuss and develop harmonised pathways for the recognition and scalability of digital therapeutics (DTx) at the local, national, and regional levels.
The partnership is part of the Alliance’s Resource Partner program, a best-in-class network of leading experts in the rapidly evolving DTx industry who collaborate with DTA members to develop resources to advance digital therapeutics to transform global healthcare. Through this relationship, Healthware will also support DTA’s Europe Policy Task Group, which is focused on understanding and informing key aspects of the European policy landscape, including Health Technology Assessment frameworks, national funding, clinician engagement, and patient access and reimbursement pathways.
This announcement follows a longstanding collaboration between the two organisations, which began with DTA’s European launch at the Frontiers Health Global Conference in 2017. The development of a pan-European coalition will deepen DTA’s presence in the region and further its mission to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare through education, advocacy, and cross-industry collaboration.
The partnership focuses on understanding and informing key aspects of the European policy landscape, including Health Technology Assessment frameworks, national funding, clinician engagement, and patient access and reimbursement pathways.
Our broader DTx Policy Coalition includes: Belgium, Catalonia (Spain), Denmark, England (UK), Estonia, Finland, France, Germany, Italy, Lithuania, Netherlands, Portugal, Sweden, as well as the broader global community including Australia, China, Japan, South Korea, cross-APAC initiatives, Canada and the United States.